PROTEIN PRODUCTION/ MONOCLONAL ANTIBODY/ TISSUE CULTURE SHARED RESOURCE (Core-544) ABSTRACT Overview: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PMTSR) supports basic and translational research projects of the UCCC members by providing authenticated cell lines, producing monoclonal antibodies and recombinant proteins, and providing real time live cell imaging of cultured cells. Equipment: In 2015, we acquired an Essen BioScience IncuCyte, which offers real time imaging of living cells to quantitate cell proliferation, apoptosis, cell migration, chemotaxis and gene expression in an automated, high throughput manner. This instrument offers new technical advantages that were not previously available to our investigators. Services: The PMTSR has assembled a collection of over 200 authenticated human cancer cell lines, which are available to UCCC members at a reduced price relative to commercial services, to encourage the responsible use of established cell lines in biomedical research. Investigators can use the PMTSR to prepare large volumes (0.5 to 10 liters) of cells for in vitro and in vivo biological studies. For over 25 years, the PMTSR has produced hybridomas and purified monoclonal antibodies for use in basic and preclinical studies. Recombinant proteins are produced using baculovirus expression systems or in mammalian (293) cells. Consultation and Education: The PMTSR has advocated for the use of authenticated cell lines in cancer research by providing seminars outlining the impact of contaminated/misidentified cell lines upon biomedical research and by providing information on cell authentication services to UCCC members. A number of seminars have been offered regarding the use and technical abilities of the IncuCyte Bioimaging system. The PMTSR director and staff routinely consult with UCCC members on projects involving offered services and technologies. Management: The PMTSR is a UCCC SR managed by the UCCC and is overseen by the Associate Director for Basic Research. CCSG funding represents 31% of the annual operating budget. The remaining 69% support is from user fees. Use of Services: Since July 2011, 157 investigators have used the PMTSR services. Fifty- seven percent of users were UCCC members, representing all UCCC Programs and resulting in 65 peer- reviewed publications. Future Directions: 1) Expand our collection of authenticated cancer cell lines and continue to make them available to UCCC members at reduced prices as a means to ensure compliance with new NIH and journal policies. 2) Collaborate with Structural Biology Shared Resource (SBSR) to develop service offering on-demand purification of recombinant proteins. 3) Support the expanded use of the IncuCyte in cancer research. 4) Contribute to international efforts to develop platforms for murine cell line authentication and when available, provide these authenticated lines to UCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-31
Application #
9657675
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
31
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Coleman, Carrie B; Lang, Julie; Sweet, Lydia A et al. (2018) Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice. J Virol 92:
Petersen, Dennis R; Orlicky, David J; Roede, James R et al. (2018) Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease. Exp Mol Pathol 105:32-36
Couts, Kasey L; Bemis, Judson; Turner, Jacqueline A et al. (2018) ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther 17:222-231
Nicholson, Andrew G; Torkko, Kathleen; Viola, Patrizia et al. (2018) Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13:205-217
Greaves, Sarah A; Peterson, Jacob N; Torres, Raul M et al. (2018) Activation of the MEK-ERK Pathway Is Necessary but Not Sufficient for Breaking Central B Cell Tolerance. Front Immunol 9:707
Thompson, Scott B; Wigton, Eric J; Krovi, Sai Harsha et al. (2018) The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo. Front Oncol 8:389
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Sang, Allison; Danhorn, Thomas; Peterson, Jacob N et al. (2018) Innate and adaptive signals enhance differentiation and expansion of dual-antibody autoreactive B cells in lupus. Nat Commun 9:3973
Ye, Haobin; Adane, Biniam; Khan, Nabilah et al. (2018) Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. Cancer Cell 34:659-673.e6
Flannery, Patrick C; DeSisto, John A; Amani, Vladimir et al. (2018) Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. Oncol Rep 39:455-464

Showing the most recent 10 out of 1634 publications